Search the Newsreel

Biomea Fusion Trial Tests Obesity Drug Combo Beyond Weight Loss

Biomea Fusion has dosed the first patient in a new arm of its OPAL study, evaluating icovamenib in combination with low-dose semaglutide for overweight or obese adults without type 2 diabetes. The study, in collaboration with the University of Leicester, aims to assess whether …

Biomea Fusion Announces First Patient Dosed in OPAL Study

Biomea Fusion has announced the dosing of the first patient in a new arm of its OPAL study, evaluating icovamenib in combination with low-dose semaglutide for overweight or obese individuals without type 2 diabetes. The study aims to assess whether adding icovamenib can enhance …

Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Biomea Fusion Inc (BMEA), detailing analyst ratings and price targets. Seven analysts have given BMEA a "Buy" rating with a target price of $6.50, representing a significant upside. The report also includes past and projected EPS figures …

Renaissance Technologies LLC Grows Position in Biomea Fusion, Inc. $BMEA

Renaissance Technologies LLC significantly increased its stake in Biomea Fusion, Inc. (NASDAQ:BMEA) by 174.3% in the first quarter, now holding 1.31 million shares, representing 1.82% of the company. Institutional ownership of Biomea Fusion remains very high at 96.72%, with several other hedge funds also …

HC Wainwright Expects Stronger Earnings for Biomea Fusion

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA) has received a "Moderate Buy" consensus rating from six analysts, with an average 12-month price target of $8.20, significantly higher than its current share price of $1.26. Institutional investors hold a substantial 96.72% of the company, and several firms, including …

Biomea Fusion, Inc. Stock 12‑Month Price Target Cut to $6.71, Implies 433% Upside

Seven analysts have revised Biomea Fusion, Inc.'s average 12-month price target down to $6.71 from $7, though this still represents a significant potential upside of approximately 433% from the August 5th closing price. The consensus rating for the stock remains a "Buy" among eight …

Citizens JMP Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $7

Citizens JMP has reiterated its Buy rating on Biomea Fusion (BMEA.US) but has adjusted its price target downwards to $7. This indicates a continued positive outlook on the company despite the revised valuation.

Biomea Fusion Inc (BMEA) Stock News Today

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Biomea Fusion, a clinical-stage diabetes and obesity company, reported its second quarter 2026 financial results, highlighting ongoing enrollment in Phase II clinical trials for insulin-deficient Type 2 diabetes and Type 2 diabetes patients on GLP-1 RA therapy, with data expected in Q1 and Q2 …

BioMea Q2 Loss Shrinks; Data From Phase 2 Trials For Icovamenib In Diabetes Expected In '27

(RTTNews) - Biomea Fusion, Inc. (BMEA) recorded a narrowed loss for the second quarter ended June 30, 2026, attributable to lower operating expenses. The biotech company also provided various pipeline updates. Company Profile Biomea is a clinical-stage biotechnology company developing oral small-molecule therapies for …

Biomea Fusion (NASDAQ:BMEA) Issues Earnings Results

Biomea Fusion (NASDAQ: BMEA) trims R&D, discloses going concern risk

Biomea Fusion (BMEA) Gains 2.56% to $1.2 as Key Levels Come into Focus - Take Profit Levels

Biomea Fusion Inc expected to post a loss of 22 cents a share - Earnings Preview

Biomea Fusion Inc is expected to report a loss of 22 cents per share, according to this earnings preview. The information is sourced from Refinitiv, indicating an upcoming financial announcement for the company.

BMEA Q2'26 Earnings: EPS estimate is (0.22) USD

Biomea Fusion, Inc. (BMEA) is expected to announce its Q2'26 earnings on August 3rd, with the earnings per share (EPS) anticipated to be ($0.22) USD and revenue estimated at $0 USD. The article provides a table of past and estimated revenue and EPS figures, …

Biomea Fusion (BMEA) to Post Earnings on Tuesday

Biomea Fusion Inc (BMEA) Balance Sheet

This article provides the quarterly and annual balance sheets for Biomea Fusion Inc (BMEA), detailing various financial metrics including cash and investments, total assets, liabilities, and shareholders' equity. It allows investors to assess the company's financial health, analyze fundamentals, and calculate key ratios. The …

Biomea Fusion Inc (BMEA) Income Statement

This article provides the quarterly and annual income statements for Biomea Fusion Inc (BMEA), detailing various financial metrics from Q2 2020 to Q1 2026. It includes operating expenses, R&D expenses, depreciation, operating profit, and net income, alongside basic and diluted earnings per share. Additionally, …

Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Biomea Fusion Inc (BMEA), detailing the company's stock performance, market capitalization, and various technical indicator and moving average signals. It includes a summary of buy, sell, and neutral signals from indicators such as MACD, RSI, and Stochastics, …

BMEA|Biomea Fusion Inc|Price:1.250|Chg%:-0.010

Biomea Fusion Inc. (BMEA) is a clinical-stage diabetes and obesity medicines company focused on oral covalent small molecules. The company's lead drug candidate, icovamenib, is in clinical trials for type 1 and type 2 diabetes and obesity, while BMF-650 is an investigational GLP-1 RA …

Biomea Fusion Market Sentiment

This article analyzes market sentiment for Biomea Fusion (BMEA), highlighting a "Buy" analyst consensus, high short interest (23.3%), and a bullish options flow with more calls than puts. It also lists recent analyst actions, including price target changes and rating initiations/maintenances from various firms. …

Biomea Fusion Inc (BMEA) Institutional Confidence

This article focuses on the institutional confidence in Biomea Fusion Inc (BMEA), detailing the shareholdings and activity of major institutional investors. It lists several key institutional shareholders, their respective share counts, and the percentage change in their holdings, highlighting significant movements such as Fidelity …

Insiders Buying Biomea Fusion Might Wish They Invested More, Stock Gains 12%

BMEA Forecast — Price Target — Prediction for 2027

BMEA Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock Reaction - EPS Surprise History

Biomea Fusion (BMEA) director granted 196,299 stock options at $1.15 exercise price

BIOMEA FUSION ($BMEA) Releases Q1 2026 Earnings, Stock Rises

Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

Biomea lines up four diabetes and obesity readouts before cash runs out

Biomea Fusion, Inc.'s (NASDAQ:BMEA) largest shareholders are retail investors with 55% ownership, institutions own 38%

Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know